Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer
Abstract Pancreatic cancer (PC) is a growing global burden, remaining one of the most lethal cancers of the gastrointestinal tract. Moreover, PC is resistant to various treatments such as chemotherapy, radiotherapy, and immunotherapy. New therapies are urgently needed to improve the prognosis of PC....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-022-02583-1 |
| _version_ | 1818523437161775104 |
|---|---|
| author | Wenhao Luo Yawen Wang Taiping Zhang |
| author_facet | Wenhao Luo Yawen Wang Taiping Zhang |
| author_sort | Wenhao Luo |
| collection | DOAJ |
| description | Abstract Pancreatic cancer (PC) is a growing global burden, remaining one of the most lethal cancers of the gastrointestinal tract. Moreover, PC is resistant to various treatments such as chemotherapy, radiotherapy, and immunotherapy. New therapies are urgently needed to improve the prognosis of PC. Oncolytic virus (OV) therapy is a promising new treatment option. OV is a genetically modified virus that selectively replicates in tumor cells. It can kill tumor cells without harming normal cells. The activation of tumor-specific T-cells is a unique feature of OV-mediated therapy. However, OV-mediated mono-therapeutic efficacy remains controversial, especially for metastatic or advanced patients who require systemically deliverable therapies. Hence, combination therapies will be critical to improve the therapeutic efficacy of OV-mediated therapy and prevent tumor recurrence. This review aims to investigate novel combinatorial treatments with OV therapy and explore the inner mechanism of those combined therapies, hopefully providing a new direction for a better prognosis of PC. |
| first_indexed | 2024-12-11T05:44:54Z |
| format | Article |
| id | doaj.art-56834834c6634e88a5fdba7bcd6c84a9 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-12-11T05:44:54Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-56834834c6634e88a5fdba7bcd6c84a92022-12-22T01:18:59ZengBMCCancer Cell International1475-28672022-04-0122111310.1186/s12935-022-02583-1Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancerWenhao Luo0Yawen Wang1Taiping Zhang2Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Endocrinology of National Health Commission of the People’s Republic of China, The Translational Medicine Center of Peking Union Medical College Hospital (PUMCH), PUMCH, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Pancreatic cancer (PC) is a growing global burden, remaining one of the most lethal cancers of the gastrointestinal tract. Moreover, PC is resistant to various treatments such as chemotherapy, radiotherapy, and immunotherapy. New therapies are urgently needed to improve the prognosis of PC. Oncolytic virus (OV) therapy is a promising new treatment option. OV is a genetically modified virus that selectively replicates in tumor cells. It can kill tumor cells without harming normal cells. The activation of tumor-specific T-cells is a unique feature of OV-mediated therapy. However, OV-mediated mono-therapeutic efficacy remains controversial, especially for metastatic or advanced patients who require systemically deliverable therapies. Hence, combination therapies will be critical to improve the therapeutic efficacy of OV-mediated therapy and prevent tumor recurrence. This review aims to investigate novel combinatorial treatments with OV therapy and explore the inner mechanism of those combined therapies, hopefully providing a new direction for a better prognosis of PC.https://doi.org/10.1186/s12935-022-02583-1Oncolytic virusCombination therapyPancreatic cancerNovel strategiesAnticancer efficiency |
| spellingShingle | Wenhao Luo Yawen Wang Taiping Zhang Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer Cancer Cell International Oncolytic virus Combination therapy Pancreatic cancer Novel strategies Anticancer efficiency |
| title | Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer |
| title_full | Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer |
| title_fullStr | Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer |
| title_full_unstemmed | Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer |
| title_short | Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer |
| title_sort | win or loss combination therapy does improve the oncolytic virus therapy to pancreatic cancer |
| topic | Oncolytic virus Combination therapy Pancreatic cancer Novel strategies Anticancer efficiency |
| url | https://doi.org/10.1186/s12935-022-02583-1 |
| work_keys_str_mv | AT wenhaoluo winorlosscombinationtherapydoesimprovetheoncolyticvirustherapytopancreaticcancer AT yawenwang winorlosscombinationtherapydoesimprovetheoncolyticvirustherapytopancreaticcancer AT taipingzhang winorlosscombinationtherapydoesimprovetheoncolyticvirustherapytopancreaticcancer |